Crocin Enhances Cisplatin-Induced Chemosensitivity in Human Cervical Cancer Cell Line

AUTHORS

Homa Mollaei 1 , Reyhane Hoshyar ORCID 2 , 3 , * , Mohammad Reza Abedini ORCID 2 , 4 , ** , Reza Safaralizadeh 5

1 Department of Biology, Faculty of Sciences, University of Birjand, Birjand, Iran

2 Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran

3 Microbiology and Molecular Genetics Department, Michigan State University, East Lansing, USA

4 Department of Cellular and Molecular Medicine, School of Medicine Ottawa, University of Ottawa, Ontario, Canada

5 Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran

Corresponding Authors:

How to Cite: Mollaei H, Hoshyar R, Abedini M R, Safaralizadeh R. Crocin Enhances Cisplatin-Induced Chemosensitivity in Human Cervical Cancer Cell Line, Int J Cancer Manag. 2019 ; 12(12):e94909. doi: 10.5812/ijcm.94909.

ARTICLE INFORMATION

International Journal of Cancer Management: 12 (12); e94909
Published Online: December 31, 2019
Article Type: Research Article
Received: June 3, 2019
Revised: September 1, 2019
Accepted: October 21, 2019
Crossmark
Crossmark
CHECKING
READ FULL TEXT

Abstract

Background: Anti-tumor effects of crocin have been investigated in different tumors; however, its precise molecular mechanism is not exactly elucidated.

Objectives: In the present investigation, we have studied pro-apoptotic and anti-proliferative properties of crocin and cisplatin combination on cervical cancer cells.

Methods: Cell viability and apoptosis assays were monitored by MTT, Hoechst 33258 staining methods, respectively. The expression levels of apoptotic related genes, including Bax, Bcl-2, p53 mRNA, and miR-365 were analyzed by quantitative reverse transcription- polymerase chain reaction (qRT-PCR). Using Western blot, we have also assessed the protein expression of the above apoptotic genes.

Results: The results of this study demonstrated that the combination treatment of cells with crocin and cisplatin significantly reduced the proliferation of cancer cells and induced apoptosis. Furthermore, the Bax/Bcl-2 ratio and the mRNA level of p53 markedly increased in treated cells, whereas it decreased miR-365 expression, an upstream regulator of Bcl2 and Bax.

Conclusions: Accordingly, crocin could be a potential candidate for more evaluations such as in vivo studies, since it shows a proper in vitro anticancer effect. It is also suggested that a combination of crocin and cisplatin could be applied as an effective and promising chemotherapy strategy.

1. Background

Cervical cancer is among the most common causes of gynecological cancer death (1). Like other cancers, chemotherapy along with radiotherapy and/or surgery is serving as the main treatment procedure for this cancer. Cisplatin (cis-diamminedichloroplatinum II, CDDP) is the prime member of platinum-containing anticancer drugs that bind to DNA, cause cross-link of DNA, and finally trigger cell death in a programmed manner (2).

Although chemotherapeutic agents like CDDP have prominent killing effects on tumor cells, their side effects and resistance impact after long-term usage stay significant obstacles for clinical use (3). To beat these challenges, researchers have been shedding light on the combination therapy in recent decades (4). This kind of therapy results in a lower dose of radiation or drugs, thereby reducing chemoresistance and its related side effects (4, 5). Due to the advantages of herbs, combination therapy with them is considered a potential therapeutic strategy for different cancers (6-9).

Crocin is the most significant water-soluble carotenoid from saffron (Crocus Sativus L.) (10), whose anticancer contributions have been reported in numerous cancers such as gastric (10), hepatic (11), leukemia (12), squamous cell carcinoma of tongue (12), bladder (13), pancreatic (14), breast (15) and cervical (9, 16).

2. Objectives

The present investigation intended to examine the synergistic impact of crocin on CDDP-induced cell death on human cervical cancer chemosensitivity and specified-related molecular mechanisms through apoptosis induction.

3. Methods

3.1. Chemicals and Cell Lines

The human cervical cancer cell line (OV2008) was kindly supplied by Dr. Benjamin K. Tsang’s Laboratory (University of Ottawa, Canada). Roswell Park Memorial Institute medium (RPMI-1640), phosphate-buffered saline (PBS), penicillin, streptomycin, fetal bovine serum (FBS), cell lysis buffer, trypsin/EDTA solution, dimethyl sulfoxide (DMSO), and 3-(4,5-dimetylthiazol-2-Yl)-2,5-diphenyltetrazoliumbromide (MTT) were from Gibco BRL (Grand Island, NY, USA) and Sigma (St. Louis, MO, USA), respectively. CDDP was procured from Sigma pharmaceutical company (Oakville, ON, Canada). The RNx-plus reagent was purchased from Cinnagen, Iran. DNase I enzyme and cDNA synthesis kit was obtained from Thermo Scientific, USA. Sybr green master mix and microRNA gene expression assay kit were purchased from Pars toos and Pars Genome companies (Iran), respectively. Primary antibodies used for Bax, Bcl2, p53, and GAPDH were obtained from Santa Cruz and Abcam for the last one. Chemiluminescence kit was purchased from Amersham Biosciences.

3.2. Preparation of Crocin

According to the published protocol, crocin was extracted and purified from saffron stigma (17).

3.3. Cell Culture

The OV2008 cell line was cultured in RPMI 1640 media containing 10% heat-inactivated FBS, 100 mg/mL streptomycin and 100 units/mL penicillin. After reaching the desired density, cells were treated with crocin in addition to CDDP and incubated for intended time intervals (0 - 72 h).

3.4. Cell Viability

The cytotoxic effect of the treatments on cells was measured with the MTT test pursuant to previous studies (18, 19). The cell viability was calculated by dividing the measured absorbance of the cells in each well to the average absorbance of the control cells and, then, the IC50 value (the concentration of drug, which decreases the treated cells viability by 50% in comparison to non-treated cells) was measured for the analysis of the cytotoxic efficiency, using the dose- and time-dependent curves.

The synergy index (q) was calculated by the following formula:

Equation 1.q=E A+B(EA+EB - EA × EB

E (A + B) = the inhibitory rate for crocin plus CDDP, EA and EB represented the inhibitory rates for crocin and CDDP alone, respectively.

3.5. Apoptosis Assay by Hoechst Staining

After the treatment duration, cells were trypsinated for 3 minutes and attached and detached cells were, then, pooled together and centrifuged. The pellet was resuspended into 10% phosphate-buffered formalin containing Hoechst staining 33258 (12.5 ng/mL). Using a Zeiss fluorescence microscope (magnification 400×), changes in nuclear morphology were assessed at least 200 cells in each group (20).

3.6. Extraction of RNA and Real-Time Polymerase Chain Reaction (Real-Time PCR)

Total RNA was extracted via the phenol-guanidinium thiocyanate procedure, using RNX Plus reagent. Quality and quantity of the extracted RNA were checked by the nanodrop device (BioTek, Epoch, USA). Complementary DNA was synthesized after DNase I digestion to avoid DNA contamination. The primer sequences are as follow: Bcl2, forward: GATGTGATGCCTCTGCGAAG, reverse: CATGCTGATGTCTCTGGAATCT, Bax, forward: GGTTGTCGCCCTTTTCTA, reverse: CGGAGGAAGTCCAATGTC, p53, forward: ACCACCATCCACTACAACTA, reverse: ACAAACACGCACCTCAAAGC. Before gene amplification assay, the standard curves were generated by serial dilutions of cDNA to define the efficiency of primers. Then, real-time PCR was done, utilizing the ABI Step One real-time PCR system (Applied Biosystems, Foster City, CA) with SYBR Green kit and previously reported conditions (16). β-actin gene was also applied to normalize the relative expression calculated by 2-ΔΔCT method, using the following primers: forward: TGGCACCCAGCACAATGAA, reverse: CTAAGTCATAGTCCGCCTAGAAGCA.

3.7. miRNA Expression

The miRNA expression level was measured by a specific miRNA amplification Kit performed in 3 steps based on our previous study (16). All experiments were done at least twice. U6 was chosen as an internal control and the PCR efficiency for miR-365 and U6 primers were measured, using serial dilutions of cDNA.

3.8. Western Blotting Analyses

Western blotting was accomplished as described before (20). Membranes were incubated overnight at 4°C in primary antibodies (anti-Bax and anti-Bcl2 [1:500], anti-p53 [1:1000]; Santa Cruz and anti-GAPDH [1:5000]; Abcam) and, then, incubated with horseradish peroxidase-conjugated anti-rabbit or anti-mouse secondary antibody (1:1000 - 1:10000) for 1 h at room temperature. Then, using the enhanced chemiluminescence kit, we visualized the Peroxidase activity. GAPDH was chosen as the loading control.

3.9. Statistical Analysis

The results are demonstrated as the mean ± SD for at least 3 independent experiments (n = 3). The data were analyzed by appropriate statistical tests such as one-way ANOVA and with Tukey’s post hoc test and statistical significance was inferred at P ≤ 0.05, (PRISM 5; Graph-Pad software Inc.).

4. Results

4.1. Crocin Enhanced CDDP-Decreased Cell Viability

The cytotoxic effects of various concentrations of crocin (0 - 4 mg/mL) and CDDP (0.003 mg/mL) for 0 to 72 h on OV2008 cells were determined, using MTT assay. Cytotoxic effects of each component were individually reported previously by our team (16, 18). As shown in Figure 1, the cell viability significantly decreased in treated cancer cells in a time- and concentration-dependent manner compared with unchallenged cells after 48 h with IC50 values 1.5 and 1 after 48 and 72 h, respectively. The synergistic index for the treated cells at 48 and 72 h were 1.7 and 0.9, respectively indicative of a synergism degree for 48 h (q > 1.0) and a simple additive effect at 72 h (0.9; 0.8 < q < 1.15) in the combined treatment.

Figure 1. The effect of crocin (0 – 4 mg/mL) and CDDP (0.003 mg/mL) on OV2008 cell viability after 0 - 72 h. The results are represented as the mean ± SD of triplicate (***, P < 0.001; ****, P < 0.0001); CDDP, positive control.

4.2. Combinational Treatment with Crocin and CDDP Increased Cells Apoptosis

To define the mode of cell death, OV2008 cells were cultured and treated with 0 to 3 mg/mL crocin and 0.003 mg/mL CDDP for 0 to 72 h; at least 200 cells in each treatment group were randomly assessed and expressed as the percentage of total cells for typical nuclear morphology of apoptotic cells, including nuclear condensation, shrinkage, and fragmentation. The results showed that combinational treatment led to an increase in the cell’s apoptosis at 48 to 72 h in a concentration- and time-dependent manner (Figure 2).

Figure 2. The effect of crocin (0 - 3 mg/mL) and CDDP (0.003 mg/mL) on induction of apoptosis on OV2008 after 0 - 72 h. The results are represented as the mean ± SD of triplicate (****, P < 0.0001); CDDP, positive control.

Apoptosis-induced by crocin and CDDP were associated with alteration in apoptosis-related genes and protein expression.

We determined the effect of crocin and CDDP co-treatment on apoptosis-related gene expression. Quantitative real-time PCR results showed that the combination of crocin (1.5 and 3 mg/mL) and CDDP (0.003 mg/mL) significantly up-regulated Bax (P < 0.001; Figure 3A) at 24 h and p53 (P < 0.001 and P < 0.0001; Figure 3B) at 12 and 24 h, respectively. These results were associated with the down-regulation of Bcl2 expression (P < 0.001, P < 0.0001; Figure 3C) in 12 and 24 h, respectively, in a concentration- and time-dependent manner. Crocin and cisplatin combination decreased the expression of miR-365, an up-regulator of Bax and Bcl2, at 12 and 24 h (P < 0.0001; Figure 3D).

Figure 3. The effect of crocin (1.5 and 3 mg/mL) and CDDP (0.003 mg/mL) on mRNA expression of; A, Bax; B, p53; C, Bcl2; and D, miR-365. The results are represented as the mean ± SD of triplicate (**, P < 0.01; ***, P < 0.001; ****, P < 0.0001).

To further investigate the impact of this combination treatment on the protein expression of apoptotic-related genes, using Western blotting analyses, we demonstrated that the treatment of OV2008 cells with 3 mg/mL crocin and 0.0015 and 0.003 mg/mL CDDP (individually and jointly) obviously elevated the protein level of p53 and Bax and reduced the Bcl2 protein level (Figure 4).

Figure 4. The effect of CDDP and crocin combination on apoptosis related protein expression.

5. Discussion

Cervical cancer is classified as one of the prominent cancers of women in developing countries like Iran (21)s. In spite of the current therapies’ efficiency, the unwanted side effects on normal cells and drug resistance remained the most severe problems for oncologists (22). Chemotherapeutic agents such as CDDP are often used in combination with other drugs to reach effective results. It is hopefully anticipated that drugs can produce synergistic and selective outcomes to kill cancer cells without additional side effects on the normal ones (23-26).

Nowadays, researchers have concentrated on natural products with an effective anticancer characteristic to improve therapeutic strategies for cancer (26-28). Crocin is a natural carotenoid derived from the dried stigma of the Crocus sativus flowers. Its various mechanisms of anticancer property have been reported including interaction with H1-DNA complex (29, 30), down-regulation of human telomerase catalytic subunit (11), cell cycle arrest and apoptosis induction, and antioxidant and anti-proliferative effects (31). Indeed, different studies suggested that crocin combination with other agents increased the efficiency of cancer treatment and reduced the essential dose of the drug (27, 28, 32, 33).

Recently, we have reported the effect of crocin on human cervical cancer cells apoptosis and proliferation (16). In the present investigation, we tried to evaluate the synergistic effect of crocin and CDDP on cervical cancer cell lines to determine the molecular mechanism of their action. We found that crocin augmented the effects of CDDP on cell proliferation and apoptosis. As shown in Figure 1, crocin in combination with CDDP markedly reduced OV2008 cell viability in a dose- and time-dependent manner after 48 and 72 h. In comparison with our previous study (16), the combination therapy of crocin with CDDP reduced the IC50 values of crocin from 2.7 to 1.5 mg/mL (48 h) and 1.5 to 1 mg/mL (72 h). Also, a degree of synergism and simple additive effect were evident in the combination treatment for 48 h and 72 h, respectively.

As shown in Figure 2, a combination of crocin and CDDP enhanced cell apoptosis with morphological changes such as blebbing and pyknotic nuclei. To better understand the molecular mechanism of the cytotoxicity, real-time PCR was performed to assess the expression of p53, Bax, and Bcl2. The treatment of the cells with crocin and CDDP increased p53 expression level and Bax/Bcl2 ratio. p53 was named as a prominent tumor suppressor that regulated cell cycle and programmed cell death (34). Bax family protein members including Bax and Bcl2 have a significant function in the internal pathway of apoptosis, thereby modulating apoptotic capacity and affect drug resistance (35).

On the other hand, non-coding RNAs such as microRNAs regulate gene expression in a post-transcriptional manner and their dysregulation is reported in many diseases including cancers (36). Several studies reported the deregulation of miR-365 in different cancers (37, 38). Bioinformatics and experimental data also demonstrated that Bax and Bcl2 are the two major target genes affected by this micro RNA (39). According to this evidence, we determined the expression level of miR-365 and showed that its expression decreased in treated cells. Taken together, these results suggests that combination treatment in tumor cells increases apoptosis capacity and is p53- and microRNA-dependent.

The findings suggest that crocin plays an important role in adjuvant therapy for potentiating routine chemotherapy. However, for the clinical application, it is necessary to perform confirmatory in vivo and clinical trial studies.

Acknowledgements

Footnotes

References

  • 1.

    Castellsague X. Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol. 2008;110(3 Suppl 2):S4-7. doi: 10.1016/j.ygyno.2008.07.045. [PubMed: 18760711].

  • 2.

    Prestayko AW. Cisplatin: Current status and new developments. United States: Academic Press; 2013.

  • 3.

    Chassagne D, Sismondi P, Horiot JC, Sinistrero G, Bey P, Zola P, et al. A glossary for reporting complications of treatment in gynecological cancers. Radiother Oncol. 1993;26(3):195-202. doi: 10.1016/0167-8140(93)90260-f. [PubMed: 8316648].

  • 4.

    Parhi P, Mohanty C, Sahoo SK. Nanotechnology-based combinational drug delivery: An emerging approach for cancer therapy. Drug Discov Today. 2012;17(17-8):1044-52. doi: 10.1016/j.drudis.2012.05.010. [PubMed: 22652342].

  • 5.

    Hu CM, Zhang L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem Pharmacol. 2012;83(8):1104-11. doi: 10.1016/j.bcp.2012.01.008. [PubMed: 22285912].

  • 6.

    Bhandari PR. Crocus sativus L. (saffron) for cancer chemoprevention: A mini review. J Tradit Complement Med. 2015;5(2):81-7. doi: 10.1016/j.jtcme.2014.10.009. [PubMed: 26151016]. [PubMed Central: PMC4488115].

  • 7.

    Hoshyar R, Jamali S, Fereidouni M, Abedini MR. The cytotoxic activity of Ziziphus Jujube on cervical cancer cells: In Vitro study. Cell Mol Biol (Noisy-le-grand). 2015;61(8):128-30. [PubMed: 26718441].

  • 8.

    Hoshyar R, Mahboob Z, Zarban A. The antioxidant and chemical properties of Berberis vulgaris and its cytotoxic effect on human breast carcinoma cells. Cytotechnology. 2016;68(4):1207-13. doi: 10.1007/s10616-015-9880-y. [PubMed: 25916942]. [PubMed Central: PMC4960168].

  • 9.

    Valavi M, Ghorbani Abdi Saedabad A, Hoshyar R, Mollaei H. Effects of combined crocin and epirubicin on apoptosis and cell cycle pathways in a human cervical cancer cell line. Int J Cancer Manage. 2018;11(12). e82575. doi: 10.5812/ijcm.82575.

  • 10.

    Behdani MA, Hoshyar R. Phytochemical properties of Iranian organic saffron stigma: antioxidant, anticancer and apoptotic approaches. Cell Mol Biol (Noisy-le-grand). 2016;62(14):69-73. doi: 10.14715/cmb/. [PubMed: 28145859].

  • 11.

    Noureini SK, Wink M. Antiproliferative effects of crocin in HepG2 cells by telomerase inhibition and hTERT down-regulation. Asian Pac J Cancer Prev. 2012;13(5):2305-9. doi: 10.7314/apjcp.2012.13.5.2305. [PubMed: 22901211].

  • 12.

    Tarantilis PA, Morjani H, Polissiou M, Manfait M. Inhibition of growth and induction of differentiation of promyelocytic leukemia (HL-60) by carotenoids from Crocus sativus L. Anticancer Res. 1994;14(5A):1913-8. [PubMed: 7847826].

  • 13.

    Zhao P, Luo CL, Wu XH, Hu HB, Lv CF, Ji HY. [Proliferation apoptotic influence of crocin on human bladder cancer T24 cell line]. Zhongguo Zhong Yao Za Zhi. 2008;33(15):1869-73. [PubMed: 19007019].

  • 14.

    Bakshi H, Sam S, Rozati R, Sultan P, Islam T, Rathore B, et al. DNA fragmentation and cell cycle arrest: A hallmark of apoptosis induced by crocin from kashmiri saffron in a human pancreatic cancer cell line. Asian Pac J Cancer Prev. 2010;11(3):675-9. [PubMed: 21039035].

  • 15.

    Hoshyar R, Khayati GR, Poorgholami M, Kaykhaii M. A novel green one-step synthesis of gold nanoparticles using crocin and their anti-cancer activities. J Photochem Photobiol B. 2016;159:237-42. doi: 10.1016/j.jphotobiol.2016.03.056. [PubMed: 27085640].

  • 16.

    Mollaei H, Safaralizadeh R, Babaei E, Abedini MR, Hoshyar R. The anti-proliferative and apoptotic effects of crocin on chemosensitive and chemoresistant cervical cancer cells. Biomed Pharmacother. 2017;94:307-16. doi: 10.1016/j.biopha.2017.07.052. [PubMed: 28763753].

  • 17.

    Bolhasani A, Bathaie SZ, Yavari I, Moosavi-Movahedi AA, Ghaffari M. Separation and purification of some components of Iranian saffron. Asian J chem. 2005;17(2):725.

  • 18.

    Wang PW, Abedini MR, Yang LX, Ding AA, Figeys D, Chang JY, et al. Gelsolin regulates cisplatin sensitivity in human head-and-neck cancer. Int J Cancer. 2014;135(12):2760-9. doi: 10.1002/ijc.28928. [PubMed: 24771612].

  • 19.

    Abedini MR, Erfanian N, Nazem H, Jamali S, Hoshyar R. Anti-proliferative and apoptotic effects of Ziziphus Jujube on cervical and breast cancer cells. Avicenna J Phytomed. 2016;6(2):142-8. [PubMed: 27222827]. [PubMed Central: PMC4877962].

  • 20.

    Abedini MR, Wang PW, Huang YF, Cao M, Chou CY, Shieh DB, et al. Cell fate regulation by gelsolin in human gynecologic cancers. Proc Natl Acad Sci U S A. 2014;111(40):14442-7. doi: 10.1073/pnas.1401166111. [PubMed: 25246592]. [PubMed Central: PMC4209992].

  • 21.

    Behtash N, Karimi Zarchi M, Deldar M. Preoperative prognostic factors and effects of adjuvant therapy on outcomes of early stage cervical cancer in Iran. Asian Pac J Cancer Prev. 2009;10(4):613-8. [PubMed: 19827880].

  • 22.

    Chabner BA, Friedman MA. Progress against rare and not-so-rare cancers. N Engl J Med. 1992;326(8):563-5. doi: 10.1056/NEJM199202203260811. [PubMed: 1310161].

  • 23.

    Florea AM, Busselberg D. Cisplatin as an anti-tumor drug: Cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel). 2011;3(1):1351-71. doi: 10.3390/cancers3011351. [PubMed: 24212665]. [PubMed Central: PMC3756417].

  • 24.

    Pegram MD, Slamon DJ. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. Semin Oncol. 1999;26(4 Suppl 12):89-95. [PubMed: 10482199].

  • 25.

    Homesley HD, Bundy BN, Hurteau JA, Roth LM. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: A Gynecologic Oncology Group study. Gynecol Oncol. 1999;72(2):131-7. doi: 10.1006/gyno.1998.5304. [PubMed: 10021290].

  • 26.

    Zhongbo Y, Qixiang G. Results of combinatine therapy with kanglaite plus cisplation in the treatment of malignant pleural effusion. Zhejiang Cancer J. 1998;(4):35.

  • 27.

    Vali F, Changizi V, Safa M. Synergistic apoptotic effect of crocin and paclitaxel or crocin and radiation on MCF-7 Cells, a Type of breast cancer cell line. Int J Breast Cancer. 2015;2015:139349. doi: 10.1155/2015/139349. [PubMed: 26693354]. [PubMed Central: PMC4674613].

  • 28.

    Li X, Huang T, Jiang G, Gong W, Qian H, Zou C. Synergistic apoptotic effect of crocin and cisplatin on osteosarcoma cells via caspase induced apoptosis. Toxicol Lett. 2013;221(3):197-204. doi: 10.1016/j.toxlet.2013.06.233. [PubMed: 23830991].

  • 29.

    Ashrafi M, Bathaie SZ, Taghikhani M, Moosavi-Movahedi AA. The effect of carotenoids obtained from saffron on histone H1 structure and H1-DNA interaction. Int J Biol Macromol. 2005;36(4):246-52. doi: 10.1016/j.ijbiomac.2005.05.008. [PubMed: 16087230].

  • 30.

    Bathaie SZ, Bolhasani A, Hoshyar R, Ranjbar B, Sabouni F, Moosavi-Movahedi AA. Interaction of saffron carotenoids as anticancer compounds with ctDNA, Oligo (dG.dC)15, and Oligo (dA.dT)15. DNA Cell Biol. 2007;26(8):533-40. doi: 10.1089/dna.2007.0598. [PubMed: 17688404].

  • 31.

    Hoshyar R, Bathaie SZ, Sadeghizadeh M. Crocin triggers the apoptosis through increasing the Bax/Bcl-2 ratio and caspase activation in human gastric adenocarcinoma, AGS, cells. DNA Cell Biol. 2013;32(2):50-7. doi: 10.1089/dna.2012.1866. [PubMed: 23347444].

  • 32.

    Chen S, Zhao S, Wang X, Zhang L, Jiang E, Gu Y, et al. Crocin inhibits cell proliferation and enhances cisplatin and pemetrexed chemosensitivity in lung cancer cells. Transl Lung Cancer Res. 2015;4(6):775-83. doi: 10.3978/j.issn.2218-6751.2015.11.03. [PubMed: 26798587]. [PubMed Central: PMC4700215].

  • 33.

    Gupta S, Jhamb B, Katiyar S. Abstract 4585: Crocin-supplemented cisplatin is highly effective in killing breast cancer cells than cisplatin alone. Cance Res. 2014:4585. doi: 10.1158/1538-7445.am2014-4585.

  • 34.

    Elmore S. Apoptosis: A review of programmed cell death. Toxicol Pathol. 2007;35(4):495-516. doi: 10.1080/01926230701320337. [PubMed: 17562483]. [PubMed Central: PMC2117903].

  • 35.

    Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 2006;25(34):4798-811. doi: 10.1038/sj.onc.1209608. [PubMed: 16892092].

  • 36.

    Langbein S, Frederiks WM, zur Hausen A, Popa J, Lehmann J, Weiss C, et al. Metastasis is promoted by a bioenergetic switch: New targets for progressive renal cell cancer. Int J Cancer. 2008;122(11):2422-8. doi: 10.1002/ijc.23403. [PubMed: 18302154].

  • 37.

    Nie J, Liu L, Zheng W, Chen L, Wu X, Xu Y, et al. microRNA-365, down-regulated in colon cancer, inhibits cell cycle progression and promotes apoptosis of colon cancer cells by probably targeting Cyclin D1 and Bcl-2. Carcinogenesis. 2012;33(1):220-5. doi: 10.1093/carcin/bgr245. [PubMed: 22072615].

  • 38.

    Guo SL, Ye H, Teng Y, Wang YL, Yang G, Li XB, et al. Akt-p53-miR-365-cyclin D1/cdc25A axis contributes to gastric tumorigenesis induced by PTEN deficiency. Nat Commun. 2013;4:2544. doi: 10.1038/ncomms3544. [PubMed: 24149576]. [PubMed Central: PMC3826643].

  • 39.

    Singh R, Saini N. Downregulation of BCL2 by miRNAs augments drug-induced apoptosis--a combined computational and experimental approach. J Cell Sci. 2012;125(Pt 6):1568-78. doi: 10.1242/jcs.095976. [PubMed: 22328513].

  • Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
    COMMENTS

    LEAVE A COMMENT HERE: